LifeArc: Funding, Investors & Team (Sep 2026)
A medical research organisation called LifeArc® transforms potential life science discoveries into treatments that improve patients' lives. We specialise in early-stage translation, which involves developing laboratory-based scientific discoveries to the point at which they may be transformed into the newest diagnoses, treatments, and cures. We are self-funding. We have been working on this for more than 25 years, and our efforts have produced four licenced drugs as well as an antibiotic resistance diagnostic. This includes an antimicrobial resistance test, as well as Keytruda® (cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis), and Entyvio® (Crohn's disease). Visit www.lifearcorg to learn more about our work, or follow us on LinkedIn or Twitter (@lifearc1).
LifeArc has raised $1.1M across 1 funding round on record, the most recent an undisclosed round of $1.1M announced in Jan 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LifeArc Company Profile and Key Stats
Latest funding round on record: Jan 2023.
LifeArc Funding Rounds
LifeArc Founders and Leadership Team
Contact details for the LifeArc team: 1 of 1 has an email address on file.
Start 14-day free trial →LifeArc Funding Compared to Other Biotechnology Startups
LifeArc's latest round of $1.1M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LifeArc in Biotechnology and London
Companies Similar to LifeArc
Alchemab is harnessing the naturally protective power of patient antibodies to keep people free of…
Biodexa Pharmaceuticals is an international specialty pharmaceutical company focused on oncology and other…
Concert Bio helps businesses create optimal microbial communities.
RQ Bio is a biotechnology company that develops long-acting monoclonal antibodies against seasonal influenza…
N4 Pharma is a drug reformulation company focused on developing and out licensing new versions of existing…
Laverock Therapeutics is working on developing a system for suppressing genes, which can be used to create…
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
IMU is a discovery engine mapping the immune system to advance precision medicine.
Mykor is a climate tech start-up. It decarbonizes the construction industry by manufacturing carbon-negative…
Neurovalens provides cutting-edge solutions in the realms of neuroscience, bioscience, and neurophysiology.…
Voxmind's biometric confirmation and authentication platform that provides voice based biometrics that helps…
Five is a biometric payment services company that offers thumb recognition technology for safe transactions.
LifeArc Funding FAQs
What does LifeArc do?
A medical research organisation called LifeArc® transforms potential life science discoveries into treatments that improve patients' lives. We specialise in early-stage translation, which involves developing laboratory-based scientific discoveries to the point at which they may be transformed into the newest diagnoses, treatments, and cures. We are self-funding. We have been working on this for more than 25 years, and our efforts have produced four licenced drugs as well as an antibiotic resistance diagnostic. This includes an antimicrobial resistance test, as well as Keytruda® (cancer), Actemra® (rheumatoid arthritis), Tysabri® (multiple sclerosis), and Entyvio® (Crohn's disease). Visit www.lifearcorg to learn more about our work, or follow us on LinkedIn or Twitter (@lifearc1).
How much funding has LifeArc raised?
LifeArc has raised $1.1M across 1 round on record. The most recent is an undisclosed round of $1.1M announced in Jan 2023.
When did LifeArc last raise funding?
LifeArc's most recent funding round on record is an undisclosed round of $1.1M, announced in Jan 2023.
Who is the CEO of LifeArc?
Melanie Lee is listed as CEO at LifeArc.
Where is LifeArc headquartered?
LifeArc is based in London, England, United Kingdom.
How many employees does LifeArc have?
LifeArc is in the 251-500 employee band.
How does LifeArc's funding compare to other Biotechnology startups?
LifeArc's latest round of $1.1M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's LifeArc Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LifeArc is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.